Summary

• Trend Spotter buy signal.
• 14 new highs and up 73.03% in the last month.
• 50.52% gain since IPO.

The Barchart Chart of the Day belongs to the rare disease treatment company Centogene (OTC: CNTG). I found the stock by sorting Barchart's New All-Time High list first by the most frequent number of new highs in the last month, then used the Flipchart feature to review the charts for consistent price appreciation.

Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The Company's goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using their knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers.   It operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene B.V. was founded in 2006 and is headquartered in Rostock, Germany. 

(Click on image to enlarge)

Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.

Barchart technical indicators:

• 50.52% gain since its IPO
• Trend Spotter buy signal
• Above its 20 and 50 day moving averages
• 14 new highs and up 73.03% in the last month
• Relative Strength Index 79.70%
• Technical support level at 17.83
• Recently traded at 18.80 with a 50 day moving average of 12.49

Fundamental factors:

• Market Cap $378 million
• Revenue expected to grow 28.40% next year
• Earnings estimated to increase 58.10% next year
• Wall Street analysts issued 5 strong buy recommendations on the stock
• Only 197 investors are monitoring the stock on Seeking Alpha